Aarti Pharmalabs Limited
NSE: AARTIPHARM BSE: AARTIPHARM
NSE
764.40
-30.35 (-3.82%)
Prev Close
794.75
Open Price
750
Volume
555,300
Today Low / High
744.7 / 789.3
52 WK Low / High
574.45 / 971
Range
726 - 803
BSE
765.55
-30.40 (-3.82%)
Prev Close
795.95
Open Price
748.05
Volume
22,994
Today Low / High
747.7 / 788.5
52 WK Low / High
557.2 / 971.5
Range
727 - 804
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 764.4 (target range: 726 - 803), reflecting a change of -30.35 (-3.81881%). On the BSE, it is listed at 765.55 (target range: 727 - 804), showing a change of -30.4 (-3.81934%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
09 Feb
785.00
1.24%
06 Feb
783.35
-0.84%
05 Feb
776.65
0.86%
04 Feb
785.00
-1.06%
03 Feb
800.00
-0.48%
02 Feb
737.20
4.65%
01 Feb
753.30
-2.19%
30 Jan
743.00
1.37%
29 Jan
758.75
-1.20%
28 Jan
766.00
-0.45%
27 Jan
767.30
-0.10%
23 Jan
761.60
0.93%
22 Jan
793.90
-4.25%
21 Jan
754.35
5.24%
20 Jan
779.00
-3.38%
19 Jan
796.10
-2.39%
16 Jan
796.80
0.77%
14 Jan
769.00
2.97%
13 Jan
766.15
-0.19%
Aarti Pharmalabs Limited Graph
Aarti Pharmalabs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Aarti Pharmalabs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 764.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 765.55 | 773.21 | 695.88 - 850.53 |
| 780.86 | 624.69 - 937.03 | ||
| 788.52 | 551.96 - 1,025.07 | ||
| Bearish Scenario | 765.55 | 757.89 | 682.11 - 833.68 |
| 750.24 | 600.19 - 900.29 | ||
| 742.58 | 519.81 - 965.36 |
Overview of Aarti Pharmalabs Limited
ISIN
INE0LRU01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
235,004
Market Cap
72,041,936,907
Last Dividend
5
Official Website
IPO Date
2023-01-30
DCF Diff
-1,115.96
DCF
1,829
Financial Ratios Every Investor Needs
Stock Dividend of AARTIPHARM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-15 | September 15, 25 | 2.5 | 2.5 | 2025-09-15 | 2025-10-20 | |
| 2025-02-14 | February 14, 25 | 2.5 | 2.5 | 2025-02-14 | 2025-03-07 | |
| 2024-07-31 | July 31, 24 | 1 | 1 | 2024-07-31 | 2024-09-02 | |
| 2024-02-16 | February 16, 24 | 2 | 2 | 2024-02-19 | 2024-03-08 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,115.07 Cr | 1,127.88 Cr | 987.20 Cr | 0.4667 | 32.83 Cr | 163.13 Cr | 377.47 Cr | 272.40 Cr | 30.06 | 474.49 Cr | 0.1288 |
| 2024-03-31 | 1,815.51 Cr | 1,424.71 Cr | 390.80 Cr | 0.2153 | 8.37 Cr | 12.39 Cr | 281.49 Cr | 216.90 Cr | 23.93 | 390.94 Cr | 0.1195 |
| 2023-03-31 | 1,945.23 Cr | 1,531.36 Cr | 413.87 Cr | 0.2128 | 13.96 Cr | 14.44 Cr | 279.51 Cr | 193.49 Cr | 21.35 | 344.37 Cr | 0.0995 |
| 2022-03-31 | 1,192.03 Cr | 879.70 Cr | 312.33 Cr | 0.2620 | 7.16 Cr | 1.51 Cr | 164.83 Cr | 122.25 Cr | 13.49 | 197.84 Cr | 0.1026 |
| 2021-03-31 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.0000 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -0.18 | 0.00 Cr | 0.0000 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 8.65 Cr | 2,906.41 Cr | 916.50 Cr | 1,989.9064 Cr | 413.12 Cr | 404.47 Cr | 587.58 Cr | 1,410.70 Cr | 0.00 Cr | 0.00 Cr | 29.24 Cr | 657.0495 Cr |
| 2024-03-31 | 23.63 Cr | 2,582.11 Cr | 825.07 Cr | 1,757.0400 Cr | 285.25 Cr | 261.62 Cr | 642.86 Cr | 1,105.45 Cr | 0.00 Cr | 0.00 Cr | 42.63 Cr | 694.3891 Cr |
| 2023-03-31 | 12.12 Cr | 2,244.02 Cr | 685.54 Cr | 1,558.4866 Cr | 215.31 Cr | 203.19 Cr | 602.04 Cr | 988.57 Cr | 0.00 Cr | 1.32 Cr | 41.38 Cr | 600.6234 Cr |
| 2022-03-31 | 83.27 Cr | 2,039.90 Cr | 653.42 Cr | 1,386.4778 Cr | 341.40 Cr | 258.13 Cr | 475.45 Cr | 945.31 Cr | 0.00 Cr | 0.00 Cr | 32.23 Cr | 580.6649 Cr |
| 2021-03-31 | 0.25 Cr | 0.25 Cr | 0.02 Cr | 0.2267 Cr | 0.02 Cr | -0.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.0219 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 331.5615 Cr | -413.8977 Cr | 65.4350 Cr | -70.4759 Cr | -16.9012 Cr | 6.7337 Cr | -443.8784 Cr | 272.4048 Cr | 127.8608 Cr | -31.7191 Cr | 55.2790 Cr |
| 2024-03-31 | 216.3546 Cr | -214.5644 Cr | 9.7235 Cr | 17.5695 Cr | 11.5137 Cr | 23.6349 Cr | -155.6042 Cr | 216.9020 Cr | 49.9934 Cr | -18.1252 Cr | -39.6600 Cr |
| 2023-03-31 | 250.1154 Cr | -157.8030 Cr | -163.4646 Cr | 130.4585 Cr | -71.1522 Cr | 12.1212 Cr | -119.6569 Cr | 260.7747 Cr | -124.2877 Cr | -18.1252 Cr | -126.6600 Cr |
| 2022-03-31 | -43.7038 Cr | -138.7389 Cr | 260.3834 Cr | -184.8558 Cr | 83.0234 Cr | 83.2734 Cr | -141.1520 Cr | 155.3804 Cr | 272.3422 Cr | 0.0000 Cr | -55.9920 Cr |
| 2021-03-31 | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 0.2500 Cr | 0.0000 Cr | -0.0046 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 418.33 Cr | 277.96 Cr | 140.38 Cr | 0.3356 | 49.95 Cr | 27.92 Cr | 3.08 | 74.77 Cr | 0.0667 |
| 2025-06-30 | 386.19 Cr | 169.41 Cr | 216.79 Cr | 0.5613 | 72.45 Cr | 49.50 Cr | 5.46 | 95.04 Cr | 0.1282 |
| 2025-03-31 | 563.78 Cr | 278.75 Cr | 285.03 Cr | 0.5056 | 122.81 Cr | 88.34 Cr | 9.75 | 144.54 Cr | 0.1567 |
| 2024-12-31 | 537.78 Cr | 275.31 Cr | 262.47 Cr | 0.4881 | 105.57 Cr | 73.99 Cr | 8.16 | 133.64 Cr | 0.1376 |
| 2024-09-30 | 458.03 Cr | 235.58 Cr | 222.45 Cr | 0.4857 | 72.79 Cr | 54.62 Cr | 6.03 | 98.16 Cr | 0.1193 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 55.56 Cr | 0.00 Cr | 55.56 Cr | 470.63 Cr | 620.59 Cr | 1,326.30 Cr | 1,560.96 Cr | 3,265.90 Cr | 1,219.70 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 56.21 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,989.91 Cr |
| 2025-03-31 | 8.65 Cr | 49.12 Cr | 56.21 Cr | 576.42 Cr | 587.58 Cr | 1,322.17 Cr | 1,410.70 Cr | 2,906.41 Cr | 916.50 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 99.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,856.73 Cr |
| 2024-09-30 | 41.35 Cr | 58.16 Cr | 99.51 Cr | 434.38 Cr | 719.80 Cr | 1,376.67 Cr | 1,228.35 Cr | 2,776.51 Cr | 919.79 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 49.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 88.34 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 73.99 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 54.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 55.45 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,707.80 | ₹4,097,584,261,766.00 | ₹1,869,940.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,175.50 | ₹1,639,401,215,790.00 | ₹237,885.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,079.60 | ₹1,380,722,017,024.00 | ₹192,731.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,256.00 | ₹1,045,705,646,640.00 | ₹1,412,748.00 |
| Lupin Limited | LUPIN | ₹2,204.10 | ₹1,007,203,049,779.00 | ₹692,179.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹887.30 | ₹892,831,419,327.00 | ₹2,272,624.00 |
| Mankind Pharma Limited | MANKIND | ₹2,073.10 | ₹855,786,194,763.00 | ₹260,047.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,811.50 | ₹694,851,997,500.00 | ₹84,504.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,124.10 | ₹652,879,104,414.00 | ₹8,584,281.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,958.00 | ₹552,549,184,022.00 | ₹278,901.00 |
| Laurus Labs Limited | LAURUSLABS | ₹966.35 | ₹521,690,408,016.00 | ₹1,173,246.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,426.20 | ₹361,832,955,712.00 | ₹111,985.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,891.30 | ₹361,226,369,671.00 | ₹123,095.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,923.10 | ₹308,710,523,713.00 | ₹180,306.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,510.30 | ₹286,311,407,162.00 | ₹143,802.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,429.10 | ₹232,217,558,718.00 | ₹2,151,502.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,960.50 | ₹224,012,500,000.00 | ₹10,901.00 |
| Eris Lifesciences Limited | ERIS | ₹1,473.70 | ₹200,742,832,267.00 | ₹52,139.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,502.00 | ₹173,229,161,278.00 | ₹169,474.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹801.90 | ₹157,623,969,136.00 | ₹23,722.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹846.95 | ₹151,697,104,397.00 | ₹446,950.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹936.40 | ₹148,297,432,027.00 | ₹106,196.00 |
| Granules India Limited | GRANULES | ₹581.00 | ₹140,990,523,996.00 | ₹962,030.00 |
| Cohance Lifesciences Limited | COHANCE | ₹353.55 | ₹135,256,612,347.00 | ₹490,988.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,731.70 | ₹131,629,453,963.00 | ₹194,129.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹951.75 | ₹116,813,988,000.00 | ₹55,158.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,498.00 | ₹91,263,402,236.00 | ₹43,098.00 |
| Viyash Scientific Limited | VIYASH | ₹205.01 | ₹89,426,501,651.00 | ₹532,071.00 |
| Strides Pharma Science Limited | STAR | ₹882.50 | ₹81,342,420,105.00 | ₹271,037.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹468.75 | ₹71,766,589,688.00 | ₹129,048.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹764.40 | ₹69,290,791,534.00 | ₹555,300.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹339.70 | ₹66,439,142,895.00 | ₹1,102,745.00 |
| FDC Limited | FDC | ₹397.10 | ₹64,651,884,356.00 | ₹115,013.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹140.55 | ₹45,611,509,193.00 | ₹766,583.00 |
| Innova Captab Limited | INNOVACAP | ₹709.20 | ₹40,583,919,647.00 | ₹15,916.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹338.45 | ₹36,879,293,939.00 | ₹34,394.00 |
| Suven Life Sciences Limited | SUVEN | ₹158.42 | ₹36,036,431,080.00 | ₹148,600.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹688.55 | ₹34,922,639,748.00 | ₹49,277.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹379.50 | ₹34,636,965,000.00 | ₹130,770.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,071.70 | ₹34,263,877,376.00 | ₹15,501.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹317.10 | ₹31,799,582,653.00 | ₹40,449.00 |
Key Executives
President of R&D
S. Patravale
Gender: Not Specified
Year Born:
Head of Operations & Manufacturing, CDMO & CMO
Naidu
Gender: male
Year Born:
Head of Business Development & Direct Procurement
Jasmin Mehta
Gender: male
Year Born:
Company Secretary & Compliance Officer
Jeevan Bhargav Mondkar
Gender: male
Year Born:
MD & Director
Narendra Jagannath Salvi
Gender: male
Year Born: 1964
Chief Financial Officer
Piyush Lakhani
Gender: male
Year Born:
Head of API Export Regulated and R&D Management
Sachin Patil
Gender: male
Year Born:
Chief Technology Officer
Shrihari S. Mane
Gender: male
Year Born:
Senior General Manager of HR & Admin
Sudhakar Shetty
Gender: male
Year Born:
Vice Chairperson & MD
Hetal Gogri Gala
Gender: female
Year Born: 1975
FAQs about Aarti Pharmalabs Limited
Who is the CEO of the company?
The CEO is Hetal Gogri Gala.
What is the current market price of the stock?
The current price is ₹794.75.
What is the 52-week price range?
The range is ₹574.45-971.
What is the market capitalization of the company?
The market capitalization is ₹7,204.19 crores.
What is the dividend yield?
The dividend yield is 0.63%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 30.05.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Aarti Pharmalabs Limited (ISIN: INE0LRU01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹7,204.19 crores and an average daily volume of 235,004 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹5.